Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
BTIG sees Legend commercializing Carvykti in earlier lines after study hits goal » 11:56
01/27/23
01/27
11:56
01/27/23
11:56
LEGN

Legend Biotech

$53.12 /

-0.75 (-1.39%)

, JNJ

Johnson & Johnson

$168.69 /

-0.16 (-0.09%)

After Legend Biotech…

After Legend Biotech (LEGN) and partner Johnson and Johnson (JNJ) announced that CARTITUDE-4, the Phase 3 study evaluating Carvykti for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma, met its primary endpoint, BTIG analyst Justin Zelin said the firm views this "highly anticipated readout" of the study "positively" and expects that Legend and J&J will commercialize Carvykti in earlier lines of therapy. The firm, which sees the news as a confirmatory event that supports Carvykti use in earlier lines against active standard of care comparator in "a robust phase 3 study," thinks this could "cement" a position as "a best-in-class autologous BCMA CAR-T therapy" in multiple myeloma. BTIG has a Buy rating and $75 price target on Legend shares.

ShowHide Related Items >><<
LEGN Legend Biotech
$53.12 /

-0.75 (-1.39%)

JNJ Johnson & Johnson
$168.69 /

-0.16 (-0.09%)

LEGN Legend Biotech
$53.12 /

-0.75 (-1.39%)

01/27/23 Piper Sandler
Piper keeps $78 target on Legend Biotech after Carvykti trial hits
01/25/23 Barclays
Legend Biotech price target raised to $65 from $53 at Barclays
12/20/22 Piper Sandler
Piper recommends 'down market cap' biotech exposure for 2023
12/20/22 Piper Sandler
Piper Sandler names three top biotechnology picks for 2023
JNJ Johnson & Johnson
$168.69 /

-0.16 (-0.09%)

01/25/23 JMP Securities
J&J conference call comments 'a good sign' for Protagonist, says JMP Securities
01/24/23 H.C. Wainwright
Fate Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
01/18/23 SVB Securities
Moderna price target raised to $111 from $102 at SVB Securities
JNJ Johnson & Johnson
$168.69 /

-0.16 (-0.09%)

  • 27
    Jul
JNJ Johnson & Johnson
$168.69 /

-0.16 (-0.09%)

LEGN Legend Biotech
$53.12 /

-0.75 (-1.39%)

JNJ Johnson & Johnson
$168.69 /

-0.16 (-0.09%)

JNJ Johnson & Johnson
$168.69 /

-0.16 (-0.09%)

Recommendations
Piper keeps $78 target on Legend Biotech after Carvykti trial hits » 10:49
01/27/23
01/27
10:49
01/27/23
10:49
LEGN

Legend Biotech

/

+

, JNJ

Johnson & Johnson

$168.29 /

-0.56 (-0.33%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating on Legend Biotech (LEGN) with a $78 price target after the company announced that CARTITUDE-4, the Phase 3 study evaluating Carvykti for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma, met its primary endpoint. The analyst anticipates Legend and Johnson & Johnson's Janssen will report data at the American Society of Clinical Oncology meeting in June and file a supplemental Biologics License Application which could expand Carvykti's label into earlier lines of therapy. Piper continues to forecast Carvykti growth of 157% to $344M in 2023. It notes that Janssen projects peak Carvykti sales of $5B.

ShowHide Related Items >><<
LEGN Legend Biotech
/

+

JNJ Johnson & Johnson
$168.29 /

-0.56 (-0.33%)

LEGN Legend Biotech
/

+

01/25/23 Barclays
Legend Biotech price target raised to $65 from $53 at Barclays
12/20/22 Piper Sandler
Piper recommends 'down market cap' biotech exposure for 2023
12/20/22 Piper Sandler
Piper Sandler names three top biotechnology picks for 2023
12/20/22 Piper Sandler
Piper Sandler ups Legend Biotech target, names top 2023 pick
JNJ Johnson & Johnson
$168.29 /

-0.56 (-0.33%)

01/25/23 JMP Securities
J&J conference call comments 'a good sign' for Protagonist, says JMP Securities
01/24/23 H.C. Wainwright
Fate Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
01/18/23 SVB Securities
Moderna price target raised to $111 from $102 at SVB Securities
01/06/23 BofA
Fate Therapeutics double downgraded to Underperform at BofA
JNJ Johnson & Johnson
$168.29 /

-0.56 (-0.33%)

  • 27
    Jul
JNJ Johnson & Johnson
$168.29 /

-0.56 (-0.33%)

LEGN Legend Biotech
/

+

JNJ Johnson & Johnson
$168.29 /

-0.56 (-0.33%)

JNJ Johnson & Johnson
$168.29 /

-0.56 (-0.33%)

Hot Stocks
Spark Therapeutics enters collaboration with Neurochase » 09:02
01/27/23
01/27
09:02
01/27/23
09:02
RHHBY

Roche

$39.38 /

-0.67 (-1.67%)

Spark Therapeutics…

Spark Therapeutics announced a strategic collaboration to develop Neurochase's proprietary delivery technology for use with selected gene therapies for rare diseases in CNS. Through this collaboration, Neurochase will bring their deep expertise in direct drug delivery technology to Spark's leading AAV platform. Neurochase is developing a proprietary drug delivery system and this collaboration enables Spark to develop selected gene therapies for CNS disorders using the Neurochase technology, which aims to improve targeted delivery of AAV gene therapy to neural structures using the method of Convection Enhanced Delivery.

ShowHide Related Items >><<
RHHBY Roche
$39.38 /

-0.67 (-1.67%)

RHHBY Roche
$39.38 /

-0.67 (-1.67%)

01/26/23 Citi
Novartis downgraded to Neutral from Buy at Citi
01/24/23 Evercore ISI
TG Therapeutics price target raised to $25 from $16 at Evercore ISI
01/18/23 Deutsche Bank
Deutsche Bank bearish on Roche heading into FY23, cuts to Sell
01/18/23 Deutsche Bank
Roche downgraded to Sell from Hold at Deutsche Bank
RHHBY Roche
$39.38 /

-0.67 (-1.67%)

RHHBY Roche
$39.38 /

-0.67 (-1.67%)

RHHBY Roche
$39.38 /

-0.67 (-1.67%)

Hot Stocks
Janssen announces unblinding of Phase 3 CARTITUDE-4 study of CARVYKTI » 08:37
01/27/23
01/27
08:37
01/27/23
08:37
JNJ

Johnson & Johnson

$168.84 /

-0.66 (-0.39%)

The Janssen…

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI versus pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Committee recommended the unblinding of the study. "The CARTITUDE-4 study represents the first Phase 3 program in our comprehensive clinical development strategy for CARVYKTI, and further demonstrates our commitment to advance the treatment of patients with relapsed/refractory multiple myeloma," said Jordan Schecter, M.D., Vice President, Clinical Development Cellular Therapy Program, Janssen Research & Development, LLC. "We look forward to the presentation of the data from the CARTITUDE-4 study at a future medical meeting."

ShowHide Related Items >><<
JNJ Johnson & Johnson
$168.84 /

-0.66 (-0.39%)

JNJ Johnson & Johnson
$168.84 /

-0.66 (-0.39%)

01/25/23 JMP Securities
J&J conference call comments 'a good sign' for Protagonist, says JMP Securities
01/24/23 H.C. Wainwright
Fate Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
01/18/23 SVB Securities
Moderna price target raised to $111 from $102 at SVB Securities
01/06/23 BofA
Fate Therapeutics double downgraded to Underperform at BofA
JNJ Johnson & Johnson
$168.84 /

-0.66 (-0.39%)

JNJ Johnson & Johnson
$168.84 /

-0.66 (-0.39%)

JNJ Johnson & Johnson
$168.84 /

-0.66 (-0.39%)

JNJ Johnson & Johnson
$168.84 /

-0.66 (-0.39%)

Recommendations
JPMorgan sees Apellis rally with FDA action date fast approaching » 07:05
01/27/23
01/27
07:05
01/27/23
07:05
APLS

Apellis

$52.81 /

+2.325 (+4.61%)

JPMorgan analyst Anupam…

JPMorgan analyst Anupam Rama says the February 26 FDA action date for Apellis Pharmaceuticals' pegcetacoplan in geographic atrophy is rapidly approaching. The firm anticipates approval of pegcetacoplan and a "best-in-class asset in the indication." On an approval, the analyst sees Apellis shares being valued in the low- to high- $80s share range versus downside to the $15-30/share range on a Complete Response Letter. It views a CRL as an "extremely low probability" scenario based on the totality of known data for pegcetacoplan.

ShowHide Related Items >><<
APLS Apellis
$52.81 /

+2.325 (+4.61%)

APLS Apellis
$52.81 /

+2.325 (+4.61%)

01/05/23 Citi
Citi would buy Apellis on dip after talking to management about CMO change
01/03/23 Needham
Vaxcyte named as Top Pick, added to Conviction list at Needham
01/03/23 Wells Fargo
Wells Fargo downgrades Apellis to Equal Weight, lowers price target to $58
01/02/23 Wells Fargo
Apellis downgraded to Equal Weight from Overweight at Wells Fargo
  • 24
    Mar
APLS Apellis
$52.81 /

+2.325 (+4.61%)

APLS Apellis
$52.81 /

+2.325 (+4.61%)

Hot Stocks
Regeneron, Sanofi announce CHMP opinion recommending EU approval for Dupixent » 05:25
01/27/23
01/27
05:25
01/27/23
05:25
REGN

Regeneron

$741.32 /

-0.06 (-0.01%)

, SNY

Sanofi

$49.00 /

+0.1 (+0.20%)

Regeneron (REGN) and…

Regeneron (REGN) and Sanofi (SNY) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion for Dupixent, recommending expanded approval in the European Union, or EU, to treat severe atopic dermatitis in children six months to five years old who are candidates for systemic therapy. The European Commission is expected to announce a final decision on the Dupixent application in the coming months. In June 2022, Dupixent was approved by the FDA for children in this age group.

ShowHide Related Items >><<
SNY Sanofi
$49.00 /

+0.1 (+0.20%)

REGN Regeneron
$741.32 /

-0.06 (-0.01%)

REGN Regeneron
$741.32 /

-0.06 (-0.01%)

01/20/23 JPMorgan
Regeneron upgraded to Overweight from Neutral at JPMorgan
01/09/23 Piper Sandler
Piper 'at a loss' to explain Regeneron Q4 miss for Eylea
12/30/22 Oppenheimer
Opco reveals three biotech stocks that will outperform in 2023
11/09/22 RBC Capital
Regeneron Eylea IPR losses 'mostly anticipated,' says RBC Capital
SNY Sanofi
$49.00 /

+0.1 (+0.20%)

12/21/22 Barclays
Sanofi, Pfizer settled first California Zantac bellwether case, says Barclays
12/16/22 Goldman Sachs
Sanofi reinstated with a Buy at Goldman Sachs
12/15/22 Guggenheim
Vaxcyte initiated with a Buy at Guggenheim on pneumococcal vaccine potential
12/14/22 UBS
Sanofi price target raised to EUR 97 from EUR 92 at UBS
SNY Sanofi
$49.00 /

+0.1 (+0.20%)

REGN Regeneron
$741.32 /

-0.06 (-0.01%)

SNY Sanofi
$49.00 /

+0.1 (+0.20%)

REGN Regeneron
$741.32 /

-0.06 (-0.01%)

SNY Sanofi
$49.00 /

+0.1 (+0.20%)

REGN Regeneron
$741.32 /

-0.06 (-0.01%)

SNY Sanofi
$49.00 /

+0.1 (+0.20%)

REGN Regeneron
$741.32 /

-0.06 (-0.01%)

Thursday
Hot Stocks
Roche launches COVID-19 PCR test to detect XBB.1.5 Omicron sub-variant » 06:33
01/26/23
01/26
06:33
01/26/23
06:33
RHHBY

Roche

$40.05 /

+0.1 (+0.25%)

Roche and its subsidiary…

Roche and its subsidiary TIB Molbiol announced they have developed a COVID-19 PCR test for researchers that detects and differentiates the latest variant of concern, XBB.1.5. "The XBB.1.5 variant is prevalent in the United States and is quickly spreading to other countries. Being able to differentiate emerging variants and understand their similarities and mutations provides a basis for experts to make predictions about their spread and respond with appropriate treatment strategies. The test, VirSNiP SARS-CoV-2 Spike F486P, is for use on the LightCycler 480 II and cobas z 480," the company said. "Roche continues to develop timely diagnostic innovations related to COVID-19 by providing valuable insights - helping scientists and physicians understand this new strain, how it differs from other variants, and the impact it may have on public health," said Matt Sause, CEO of Roche Diagnostics. "Since the start of this global health crisis, Roche has been committed to bringing effective diagnostic solutions to address unmet needs to healthcare communities worldwide."

ShowHide Related Items >><<
RHHBY Roche
$40.05 /

+0.1 (+0.25%)

RHHBY Roche
$40.05 /

+0.1 (+0.25%)

01/26/23 Citi
Novartis downgraded to Neutral from Buy at Citi
01/24/23 Evercore ISI
TG Therapeutics price target raised to $25 from $16 at Evercore ISI
01/18/23 Deutsche Bank
Deutsche Bank bearish on Roche heading into FY23, cuts to Sell
01/18/23 Deutsche Bank
Roche downgraded to Sell from Hold at Deutsche Bank
RHHBY Roche
$40.05 /

+0.1 (+0.25%)

RHHBY Roche
$40.05 /

+0.1 (+0.25%)

RHHBY Roche
$40.05 /

+0.1 (+0.25%)

Downgrade
Novartis downgraded to Neutral from Buy at Citi » 04:31
01/26/23
01/26
04:31
01/26/23
04:31
NVS

Novartis

$92.81 /

+0.775 (+0.84%)

, NVO

Novo Nordisk

$138.94 /

-1.06 (-0.76%)

, AZN

AstraZeneca

$66.62 /

+0.335 (+0.51%)

, MRK

Merck

$108.60 /

+0.065 (+0.06%)

, RHHBY

Roche

$40.05 /

+0.1 (+0.25%)

Citi analyst Andrew Baum…

Citi analyst Andrew Baum downgraded Novartis (NVS) to Neutral from Buy with a CHF 86 price target. The shares have outperformed all European pharma majors except Novo Nordisk (NVO) and AstraZeneca (AZN) due to the impact of management action in the last six months, aided by some rotation out of Roche (RHHBY), the analyst tells investors in a research note. Citi reduced Novartis earnings estimates to by up to 8% to reflect a more cautious outlook for Leqvio given competitive pressures from Merck's (MRK) oral PCSK-9 MK-0616 in the U.S. commercial and outside the U.S. market. The firm also highlights material ongoing supply constraints hindering Pluvicto's U.S. launch in prostate cancer.

ShowHide Related Items >><<
RHHBY Roche
$40.05 /

+0.1 (+0.25%)

NVS Novartis
$92.81 /

+0.775 (+0.84%)

NVO Novo Nordisk
$138.94 /

-1.06 (-0.76%)

MRK Merck
$108.60 /

+0.065 (+0.06%)

AZN AstraZeneca
$66.62 /

+0.335 (+0.51%)

NVS Novartis
$92.81 /

+0.775 (+0.84%)

01/24/23 Lake Street
Harrow Health price target raised to $24 from $17 at Lake Street
01/06/23 Morgan Stanley
Novartis downgraded to Underweight from Equal Weight at Morgan Stanley
01/03/23 JPMorgan
Novartis upgraded to Neutral from Underweight at JPMorgan
12/14/22 UBS
Novartis price target raised to CHF 84 from CHF 82 at UBS
NVO Novo Nordisk
$138.94 /

-1.06 (-0.76%)

01/18/23 Deutsche Bank
Deutsche Bank bearish on Roche heading into FY23, cuts to Sell
01/03/23 JPMorgan
Novo Nordisk price target raised to DKK 1,100 from DKK 925 at JPMorgan
01/03/23 JPMorgan
Novo Nordisk added to Analyst Focus List at JPMorgan
12/12/22 Cowen
Novo Nordisk price target raised to $145 from $130 at Cowen
AZN AstraZeneca
$66.62 /

+0.335 (+0.51%)

01/18/23 Berenberg
AstraZeneca price target raised to 126 GBp from 118 GBp at Berenberg
01/12/23 Guggenheim
Arvinas downgraded to Neutral at Guggenheim on rising ARV-471 risks
01/12/23 Barclays
CinCor Pharma downgraded to Equal Weight from Overweight at Barclays
01/05/23 BMO Capital
AstraZeneca initiated with an Outperform at BMO Capital
MRK Merck
$108.60 /

+0.065 (+0.06%)

01/04/23 BofA
Merck upgraded to Buy at BofA on consistent revenue upside
01/04/23 BofA
Merck upgraded to Buy from Neutral at BofA
01/03/23 Wells Fargo
Merck price target raised to $125 from $110 at Wells Fargo
01/03/23 Cowen
Merck price target raised to $120 from $108 at Cowen
RHHBY Roche
$40.05 /

+0.1 (+0.25%)

01/24/23 Evercore ISI
TG Therapeutics price target raised to $25 from $16 at Evercore ISI
01/18/23 Deutsche Bank
Roche downgraded to Sell from Hold at Deutsche Bank
RHHBY Roche
$40.05 /

+0.1 (+0.25%)

NVS Novartis
$92.81 /

+0.775 (+0.84%)

NVO Novo Nordisk
$138.94 /

-1.06 (-0.76%)

MRK Merck
$108.60 /

+0.065 (+0.06%)

AZN AstraZeneca
$66.62 /

+0.335 (+0.51%)

RHHBY Roche
$40.05 /

+0.1 (+0.25%)

NVS Novartis
$92.81 /

+0.775 (+0.84%)

NVO Novo Nordisk
$138.94 /

-1.06 (-0.76%)

MRK Merck
$108.60 /

+0.065 (+0.06%)

AZN AstraZeneca
$66.62 /

+0.335 (+0.51%)

RHHBY Roche
$40.05 /

+0.1 (+0.25%)

NVS Novartis
$92.81 /

+0.775 (+0.84%)

NVO Novo Nordisk
$138.94 /

-1.06 (-0.76%)

MRK Merck
$108.60 /

+0.065 (+0.06%)

AZN AstraZeneca
$66.62 /

+0.335 (+0.51%)

NVS Novartis
$92.81 /

+0.775 (+0.84%)

MRK Merck
$108.60 /

+0.065 (+0.06%)

AZN AstraZeneca
$66.62 /

+0.335 (+0.51%)

Wednesday
Recommendations
J&J conference call comments 'a good sign' for Protagonist, says JMP Securities » 14:31
01/25/23
01/25
14:31
01/25/23
14:31
PTGX

Protagonist Therapeutics

$12.92 /

+0.23 (+1.81%)

, JNJ

Johnson & Johnson

$168.79 /

+0.49 (+0.29%)

JMP Securities analyst…

JMP Securities analyst Jonathan Wolleben reiterated an Outperform rating and $21 price target on Protagonist Therapeutics (PTGX) after Johnson & Johnson (JNJ) highlighted the upcoming data and opportunity for the oral IL-23R antagonist PN-235 on its quarterly call. JMP said that the mention of PN-235 on the call seems like a good sign for the ongoing partnership with Phase 2 data from both the FRONTIER 1 and SUMMIT trials for psoriasis coming this year. The firm views the partnership with Johnson & Johnson and the progress on PN-235 as validation for Protagonist's developmental capabilities and considers downstream payments from the partnership as upside to the firm's valuation.

ShowHide Related Items >><<
PTGX Protagonist Therapeutics
$12.92 /

+0.23 (+1.81%)

JNJ Johnson & Johnson
$168.79 /

+0.49 (+0.29%)

PTGX Protagonist Therapeutics
$12.92 /

+0.23 (+1.81%)

01/17/23 Piper Sandler
Piper Sandler 'excited' about Protagonist ahead of PN-235 data
11/10/22 H.C. Wainwright
Protagonist Therapeutics price target lowered to $33 from $50 at H.C. Wainwright
08/25/22 JMP Securities
Protagonist Therapeutics resumed with an Outperform at JMP Securities
05/17/22 Piper Sandler
Protagonist Therapeutics price target lowered to $35 from $60 at Piper Sandler
JNJ Johnson & Johnson
$168.79 /

+0.49 (+0.29%)

01/24/23 H.C. Wainwright
Fate Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
01/18/23 SVB Securities
Moderna price target raised to $111 from $102 at SVB Securities
01/06/23 BofA
Fate Therapeutics double downgraded to Underperform at BofA
01/06/23 Wedbush
Fate Therapeutics downgraded to Neutral from Outperform at Wedbush
PTGX Protagonist Therapeutics
$12.92 /

+0.23 (+1.81%)

JNJ Johnson & Johnson
$168.79 /

+0.49 (+0.29%)

JNJ Johnson & Johnson
$168.79 /

+0.49 (+0.29%)

JNJ Johnson & Johnson
$168.79 /

+0.49 (+0.29%)

JNJ Johnson & Johnson
$168.79 /

+0.49 (+0.29%)

Tuesday
On The Fly
What You Missed On Wall Street On Tuesday » 16:32
01/24/23
01/24
16:32
01/24/23
16:32
XMTR

Xometry

$31.16 /

+1.94 (+6.64%)

, LYV

Live Nation

$77.00 /

+1.045 (+1.38%)

, RIVN

Rivian Automotive

$18.05 /

-0.03 (-0.17%)

, F

Ford

$12.74 /

-0.065 (-0.51%)

, PARA

Paramount

$20.83 /

-0.33 (-1.56%)

, PARAA

Paramount

$24.36 /

-0.21 (-0.85%)

, GE

General Electric

$80.72 /

+0.925 (+1.16%)

, JNJ

Johnson & Johnson

$168.30 /

-0.065 (-0.04%)

, AMZN

Amazon.com

$96.35 /

-1.16 (-1.19%)

, GOOGL

Alphabet

$97.68 /

-2.095 (-2.10%)

, GOOG

Alphabet

$99.20 /

-1.99 (-1.97%)

, $ECON

Economic Data

/

+

, SPX

S&P 500

/

+

, SPY

SPDR S&P 500 ETF Trust

$400.15 /

-0.44 (-0.11%)

, PTON

Peloton

$11.06 /

-0.585 (-5.02%)

, LULU

Lululemon

$311.35 /

-4.73 (-1.50%)

, LYFT

Lyft

$15.29 /

-0.13 (-0.84%)

, AMD

AMD

$74.72 /

-1.82 (-2.38%)

, TGT

Target

$163.54 /

-1.1 (-0.67%)

, CBAY

CymaBay

$7.63 /

+1.025 (+15.52%)

, TGTX

TG Therapeutics

$14.46 /

+1.775 (+13.99%)

, SAVA

Cassava Sciences

$29.44 /

-7.01 (-19.23%)

, MMM

3M

$115.00 /

-7.67 (-6.25%)

, MGA

Magna

$60.75 /

-4.71 (-7.20%)

, VZ

Verizon

$40.42 /

+0.795 (+2.01%)

, TRV

Travelers

$193.23 /

+6.57 (+3.52%)

, LMT

Lockheed Martin

$449.14 /

+7.5 (+1.70%)

, DHI

D.R. Horton

$97.04 /

+1.365 (+1.43%)

, PD

PagerDuty

$26.52 /

-2.33 (-8.08%)

Get caught up quickly on…

ShowHide Related Items >><<
XMTR Xometry
$31.16 /

+1.94 (+6.64%)

VZ Verizon
$40.42 /

+0.795 (+2.01%)

TRV Travelers
$193.23 /

+6.57 (+3.52%)

TGTX TG Therapeutics
$14.46 /

+1.775 (+13.99%)

TGT Target
$163.54 /

-1.1 (-0.67%)

SPY SPDR S&P 500 ETF Trust
$400.15 /

-0.44 (-0.11%)

SPX S&P 500
/

+

SAVA Cassava Sciences
$29.44 /

-7.01 (-19.23%)

RIVN Rivian Automotive
$18.05 /

-0.03 (-0.17%)

PTON Peloton
$11.06 /

-0.585 (-5.02%)

PD PagerDuty
$26.52 /

-2.33 (-8.08%)

PARAA Paramount
$24.36 /

-0.21 (-0.85%)

PARA Paramount
$20.83 /

-0.33 (-1.56%)

MMM 3M
$115.00 /

-7.67 (-6.25%)

MGA Magna
$60.75 /

-4.71 (-7.20%)

LYV Live Nation
$77.00 /

+1.045 (+1.38%)

LYFT Lyft
$15.29 /

-0.13 (-0.84%)

LULU Lululemon
$311.35 /

-4.73 (-1.50%)

LMT Lockheed Martin
$449.14 /

+7.5 (+1.70%)

JNJ Johnson & Johnson
$168.30 /

-0.065 (-0.04%)

GOOGL Alphabet
$97.68 /

-2.095 (-2.10%)

GE General Electric
$80.72 /

+0.925 (+1.16%)

F Ford
$12.74 /

-0.065 (-0.51%)

DHI D.R. Horton
$97.04 /

+1.365 (+1.43%)

CBAY CymaBay
$7.63 /

+1.025 (+15.52%)

AMZN Amazon.com
$96.35 /

-1.16 (-1.19%)

AMD AMD
$74.72 /

-1.82 (-2.38%)

XMTR Xometry
$31.16 /

+1.94 (+6.64%)

12/14/22 Lake Street
Xometry initiated with a Sell at Lake Street
12/13/22 Citi
Xometry initiated with a Buy at Citi
11/11/22 UBS
Xometry price target lowered to $45 from $55 at UBS
08/24/22 JPMorgan
JPMorgan cuts Xometry target but still sees 46% upside potential
LYV Live Nation
$77.00 /

+1.045 (+1.38%)

12/08/22 Jefferies
Live Nation price target lowered to $92 from $120 at Jefferies
11/30/22 Morgan Stanley
Live Nation price target lowered to $80 from $95 at Morgan Stanley
11/28/22 Citi
Live Nation upgraded to Buy from Neutral at Citi
11/22/22 Redburn
Redburn starts Live Nation with a Neutral
RIVN Rivian Automotive
$18.05 /

-0.03 (-0.17%)

01/25/23 Morgan Stanley
Rivian Automotive price target lowered to $28 from $55 at Morgan Stanley
01/19/23 Deutsche Bank
Rivian Automotive price target lowered to $28 from $43 at Deutsche Bank
01/11/23 Goldman Sachs
Goldman continues to prefer Tesla and GM among automakers
01/10/23 Goldman Sachs
Rivian Automotive price target lowered to $19 from $41 at Goldman Sachs
F Ford
$12.74 /

-0.065 (-0.51%)

01/25/23 JPMorgan
Ford price target lowered to $15 from $16 at JPMorgan
12/21/22 Morgan Stanley
Tesla shedding $600B of value presents buying opportunity, says Morgan Stanley
12/05/22 Jefferies
Fox Factory price target raised to $135 from $120 at Jefferies
PARA Paramount
$20.83 /

-0.33 (-1.56%)

01/12/23 Guggenheim
Paramount price target raised to $22 from $20 at Guggenheim
01/04/23 Macquarie
Paramount price target lowered to $15 from $16 at Macquarie
12/23/22 Loop Capital
Paramount cut to Sell at Loop Capital amid declining earnings and cash flow
12/23/22 Loop Capital
Paramount downgraded to Sell from Hold at Loop Capital
PARAA Paramount
$24.36 /

-0.21 (-0.85%)

GE General Electric
$80.72 /

+0.925 (+1.16%)

01/25/23 BofA
General Electric price target raised to $92 from $85 at BofA
01/12/23 UBS
General Electric price target lowered to $87 from $98 at UBS
01/09/23 BofA
General Electric price target lowered to $85 from $105 at BofA
12/16/22 Barclays
General Electric price target raised to $96 from $92 at Barclays
JNJ Johnson & Johnson
$168.30 /

-0.065 (-0.04%)

01/24/23 H.C. Wainwright
Fate Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
01/18/23 SVB Securities
Moderna price target raised to $111 from $102 at SVB Securities
01/06/23 BofA
Fate Therapeutics double downgraded to Underperform at BofA
01/06/23 Wedbush
Fate Therapeutics downgraded to Neutral from Outperform at Wedbush
AMZN Amazon.com
$96.35 /

-1.16 (-1.19%)

01/25/23 BofA
Azure guidance indicates AWS will remain concern into earnings, says BofA
01/25/23 UBS
Amazon.com price target lowered to $118 from $121 at UBS
01/24/23 Citi
Amazon RxPass a 'credible threat' to GoodRx, says Citi
01/18/23 MKM Partners
Amazon.com price target lowered to $125 from $145 at MKM Partners
GOOGL Alphabet
$97.68 /

-2.095 (-2.10%)

01/25/23 MKM Partners
Alphabet price target lowered to $120 from $130 at MKM Partners
01/25/23 Credit Suisse
Alphabet price target raised to $145 from $128 at Credit Suisse
01/22/23 Citi
Alphabet workforce reduction a positive catalyst, says Citi
01/20/23 MKM Partners
Meta Platforms price target raised to $155 from $140 at MKM Partners
GOOG Alphabet
$99.20 /

-1.99 (-1.97%)

01/24/23 Credit Suisse
Credit Suisse sees 8% Alphabet target cut in 'maximum value destruction'
01/24/23 Raymond James
Alphabet price target lowered to $116 from $120 at Raymond James
01/24/23 Raymond James
Alphabet price target lowered to $116 from $120 at Raymond James
$ECON Economic Data
/

+

10/31/22 JPMorgan
Central bank tightening has likely peaked, says JPMorgan
10/07/22 JPMorgan
JPMorgan changes November rate hike assumption after jobs data
09/26/22 JPMorgan
JPMorgan says stocks oversold amid 'encouraging' inflation signs
09/23/22 Goldman Sachs
Goldman Sachs lowers S&P 500 year-end target to 3,600
SPX S&P 500
/

+

SPY SPDR S&P 500 ETF Trust
$400.15 /

-0.44 (-0.11%)

PTON Peloton
$11.06 /

-0.585 (-5.02%)

01/24/23 MKM Partners
MKM Partners positive on Peloton heading into earnings
01/24/23 Baird
Peloton downgraded to Neutral from Outperform at Baird
11/21/22 Cowen
Peloton downgraded to Market Perform from Outperform at Cowen
11/07/22 Citi
Peloton price target lowered to $18 from $23 at Citi
LULU Lululemon
$311.35 /

-4.73 (-1.50%)

01/24/23 Bernstein
Lululemon downgraded to Underperform from Market Perform at Bernstein
01/23/23 Jefferies
Jefferies store checks find 'flaws' in Lululemon merchandising
01/13/23 Citi
Lululemon price target lowered to $350 from $400 at Citi
01/13/23 Barclays
Lululemon price target lowered to $394 from $445 at Barclays
LYFT Lyft
$15.29 /

-0.13 (-0.84%)

01/24/23 KeyBanc
KeyBanc upgrades Lyft on 'meaningful opportunity' for EBITDA lift
01/23/23 KeyBanc
Lyft upgraded to Overweight from Sector Weight at KeyBanc
01/09/23 Jefferies
Lyft assumed with a Hold at Jefferies
01/09/23 Piper Sandler
Lyft price target lowered to $16 from $37 at Piper Sandler
AMD AMD
$74.72 /

-1.82 (-2.38%)

01/24/23 Cowen
AMD remains in a very strong competitive position, says Cowen
01/24/23 Bernstein
AMD downgraded to Market Perform from Outperform at Bernstein
01/23/23 Truist
AMD price target raised to $79 from $70 at Truist
01/23/23 Barclays
AMD upgraded to Overweight from Equal Weight at Barclays
TGT Target
$163.54 /

-1.1 (-0.67%)

01/23/23 Oppenheimer
Target initiated with an Outperform at Oppenheimer
01/04/23 Wells Fargo
Wells Fargo downgrades Target to Equal Weight, lowers price target to $142
01/04/23 Wells Fargo
Target downgraded to Equal Weight from Overweight at Wells Fargo
12/21/22 Gordon Haskett
Gordon Haskett downgrades Target on 'meaningfully eroded' traffic
CBAY CymaBay
$7.63 /

+1.025 (+15.52%)

01/09/23 Piper Sandler
CymaBay collaboration in Japan further de-risks PBC data, says Piper Sandler
12/20/22 Piper Sandler
Piper recommends 'down market cap' biotech exposure for 2023
05/18/22 B. Riley
CymaBay price target lowered to $8 from $10 at B. Riley
05/16/22 H.C. Wainwright
CymaBay price target lowered to $10 from $12 at H.C. Wainwright
TGTX TG Therapeutics
$14.46 /

+1.775 (+13.99%)

01/24/23 Evercore ISI
TG Therapeutics price target raised to $25 from $16 at Evercore ISI
12/30/22 Jefferies
TG Therapeutics price target raised to $23 from $19 at Jefferies
12/30/22 Evercore ISI
TG Therapeutics price target raised to $16 from $11 at Evercore ISI
12/29/22 B. Riley
TG Therapeutics price target raised to $23 from $17 at B. Riley
SAVA Cassava Sciences
$29.44 /

-7.01 (-19.23%)

01/25/23 B. Riley
Cassava Sciences price target lowered to $28 from $44 at B. Riley
01/24/23 H.C. Wainwright
H.C. Wainwright positive on Cassava data, says buy the selloff
11/29/22 Univest Securities
Cassava Sciences price target lowered to $11 from $12 at Univest Securities
11/16/22 B. Riley
Cassava Sciences downgraded to Neutral at B. Riley amid limited disclosures
MMM 3M
$115.00 /

-7.67 (-6.25%)

01/25/23 Wells Fargo
3M price target lowered to $115 from $125 at Wells Fargo
01/25/23 UBS
3M price target lowered to $115 from $124 at UBS
01/25/23 Barclays
3M price target lowered to $122 from $130 at Barclays
12/09/22 Citi
3M price target raised to $126 from $117 at Citi
MGA Magna
$60.75 /

-4.71 (-7.20%)

01/25/23 TD Securities
Magna downgraded to Hold from Buy at TD Securities
01/13/23 Citi
Magna price target raised to $66 from $62 at Citi
01/09/23 BofA
Magna downgraded to Neutral from Buy at BofA
12/14/22 Wells Fargo
Magna downgraded on likely sector correction at Wells Fargo
VZ Verizon
$40.42 /

+0.795 (+2.01%)

01/25/23 Cowen
Verizon price target lowered to $49 from $55 at Cowen
01/25/23 RBC Capital
Verizon price target lowered to $40 from $42 at RBC Capital
01/13/23 Truist
American Tower price target lowered to $275 from $325 at Truist
12/19/22 MoffettNathanson
AT&T downgraded to Underperform at MoffettNathanson after 'dramatic bounce'
TRV Travelers
$193.23 /

+6.57 (+3.52%)

01/25/23 MKM Partners
Travelers price target raised to $230 from $220 at MKM Partners
01/25/23 Raymond James
Travelers price target raised to $220 from $200 at Raymond James
01/19/23 BMO Capital
Travelers initiated with an Outperform at BMO Capital
01/10/23 Evercore ISI
Hartford downgraded at Evercore ISI, more relative upside seen elsewhere
LMT Lockheed Martin
$449.14 /

+7.5 (+1.70%)

01/25/23 Credit Suisse
Lockheed Martin price target raised to $408 from $384 at Credit Suisse
01/25/23 Argus
Lockheed Martin a 'value opportunity', says Argus
01/25/23 Wells Fargo
Lockheed Martin price target raised to $422 from $417 at Wells Fargo
01/25/23 Susquehanna
Lockheed Martin price target raised to $512 from $510 at Susquehanna
DHI D.R. Horton
$97.04 /

+1.365 (+1.43%)

01/25/23 BTIG
D.R. Horton price target raised to $108 from $101 at BTIG
01/25/23 JMP Securities
D.R. Horton price target raised to $115 from $95 at JMP Securities
01/25/23 Wedbush
Wedbush downgrades D.R. Horton to Neutral, lowers price target to $96
01/25/23 Wedbush
D.R. Horton downgraded to Neutral from Outperform at Wedbush
PD PagerDuty
$26.52 /

-2.33 (-8.08%)

01/20/23 Morgan Stanley
PagerDuty upgraded to Overweight from Equal Weight at Morgan Stanley
12/02/22 Canaccord
PagerDuty price target lowered to $31 from $32 at Canaccord
12/02/22 Baird
PagerDuty price target lowered to $32 from $35 at Baird
10/26/22 Truist
PagerDuty price target lowered to $30 from $35 at Truist
XMTR Xometry
$31.16 /

+1.94 (+6.64%)

VZ Verizon
$40.42 /

+0.795 (+2.01%)

TRV Travelers
$193.23 /

+6.57 (+3.52%)

TGTX TG Therapeutics
$14.46 /

+1.775 (+13.99%)

TGT Target
$163.54 /

-1.1 (-0.67%)

SAVA Cassava Sciences
$29.44 /

-7.01 (-19.23%)

RIVN Rivian Automotive
$18.05 /

-0.03 (-0.17%)

PTON Peloton
$11.06 /

-0.585 (-5.02%)

PD PagerDuty
$26.52 /

-2.33 (-8.08%)

PARA Paramount
$20.83 /

-0.33 (-1.56%)

MMM 3M
$115.00 /

-7.67 (-6.25%)

MGA Magna
$60.75 /

-4.71 (-7.20%)

LYV Live Nation
$77.00 /

+1.045 (+1.38%)

LYFT Lyft
$15.29 /

-0.13 (-0.84%)

LULU Lululemon
$311.35 /

-4.73 (-1.50%)

LMT Lockheed Martin
$449.14 /

+7.5 (+1.70%)

JNJ Johnson & Johnson
$168.30 /

-0.065 (-0.04%)

GOOGL Alphabet
$97.68 /

-2.095 (-2.10%)

GE General Electric
$80.72 /

+0.925 (+1.16%)

F Ford
$12.74 /

-0.065 (-0.51%)

DHI D.R. Horton
$97.04 /

+1.365 (+1.43%)

CBAY CymaBay
$7.63 /

+1.025 (+15.52%)

AMZN Amazon.com
$96.35 /

-1.16 (-1.19%)

AMD AMD
$74.72 /

-1.82 (-2.38%)

  • 24
    Jan
XMTR Xometry
$31.16 /

+1.94 (+6.64%)

VZ Verizon
$40.42 /

+0.795 (+2.01%)

TGT Target
$163.54 /

-1.1 (-0.67%)

SPX S&P 500
/

+

SAVA Cassava Sciences
$29.44 /

-7.01 (-19.23%)

RIVN Rivian Automotive
$18.05 /

-0.03 (-0.17%)

PTON Peloton
$11.06 /

-0.585 (-5.02%)

PARAA Paramount
$24.36 /

-0.21 (-0.85%)

PARA Paramount
$20.83 /

-0.33 (-1.56%)

MMM 3M
$115.00 /

-7.67 (-6.25%)

LYV Live Nation
$77.00 /

+1.045 (+1.38%)

LYFT Lyft
$15.29 /

-0.13 (-0.84%)

LULU Lululemon
$311.35 /

-4.73 (-1.50%)

LMT Lockheed Martin
$449.14 /

+7.5 (+1.70%)

JNJ Johnson & Johnson
$168.30 /

-0.065 (-0.04%)

GOOGL Alphabet
$97.68 /

-2.095 (-2.10%)

GE General Electric
$80.72 /

+0.925 (+1.16%)

F Ford
$12.74 /

-0.065 (-0.51%)

DHI D.R. Horton
$97.04 /

+1.365 (+1.43%)

AMZN Amazon.com
$96.35 /

-1.16 (-1.19%)

AMD AMD
$74.72 /

-1.82 (-2.38%)

$ECON Economic Data
/

+

XMTR Xometry
$31.16 /

+1.94 (+6.64%)

VZ Verizon
$40.42 /

+0.795 (+2.01%)

TRV Travelers
$193.23 /

+6.57 (+3.52%)

TGTX TG Therapeutics
$14.46 /

+1.775 (+13.99%)

SAVA Cassava Sciences
$29.44 /

-7.01 (-19.23%)

RIVN Rivian Automotive
$18.05 /

-0.03 (-0.17%)

PTON Peloton
$11.06 /

-0.585 (-5.02%)

PD PagerDuty
$26.52 /

-2.33 (-8.08%)

PARAA Paramount
$24.36 /

-0.21 (-0.85%)

PARA Paramount
$20.83 /

-0.33 (-1.56%)

MGA Magna
$60.75 /

-4.71 (-7.20%)

LYV Live Nation
$77.00 /

+1.045 (+1.38%)

LYFT Lyft
$15.29 /

-0.13 (-0.84%)

LULU Lululemon
$311.35 /

-4.73 (-1.50%)

LMT Lockheed Martin
$449.14 /

+7.5 (+1.70%)

JNJ Johnson & Johnson
$168.30 /

-0.065 (-0.04%)

GOOGL Alphabet
$97.68 /

-2.095 (-2.10%)

GE General Electric
$80.72 /

+0.925 (+1.16%)

F Ford
$12.74 /

-0.065 (-0.51%)

DHI D.R. Horton
$97.04 /

+1.365 (+1.43%)

CBAY CymaBay
$7.63 /

+1.025 (+15.52%)

AMZN Amazon.com
$96.35 /

-1.16 (-1.19%)

$ECON Economic Data
/

+

VZ Verizon
$40.42 /

+0.795 (+2.01%)

TRV Travelers
$193.23 /

+6.57 (+3.52%)

TGTX TG Therapeutics
$14.46 /

+1.775 (+13.99%)

TGT Target
$163.54 /

-1.1 (-0.67%)

SPX S&P 500
/

+

SAVA Cassava Sciences
$29.44 /

-7.01 (-19.23%)

RIVN Rivian Automotive
$18.05 /

-0.03 (-0.17%)

PTON Peloton
$11.06 /

-0.585 (-5.02%)

PARA Paramount
$20.83 /

-0.33 (-1.56%)

MMM 3M
$115.00 /

-7.67 (-6.25%)

LYV Live Nation
$77.00 /

+1.045 (+1.38%)

LYFT Lyft
$15.29 /

-0.13 (-0.84%)

LULU Lululemon
$311.35 /

-4.73 (-1.50%)

LMT Lockheed Martin
$449.14 /

+7.5 (+1.70%)

JNJ Johnson & Johnson
$168.30 /

-0.065 (-0.04%)

GOOGL Alphabet
$97.68 /

-2.095 (-2.10%)

GOOG Alphabet
$99.20 /

-1.99 (-1.97%)

GE General Electric
$80.72 /

+0.925 (+1.16%)

F Ford
$12.74 /

-0.065 (-0.51%)

DHI D.R. Horton
$97.04 /

+1.365 (+1.43%)

AMZN Amazon.com
$96.35 /

-1.16 (-1.19%)

AMD AMD
$74.72 /

-1.82 (-2.38%)

SPY SPDR S&P 500 ETF Trust
$400.15 /

-0.44 (-0.11%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.